Concept Life Sciences has extensive experience of in vitro screening and delivers customised, instructive and efficient screening programs to progress fully characterised hits through drug discovery programs.
Concept offers medium-throughput screening approaches using biophysical, biochemical, phenotypic and cell-based assays. Our technologies allow cost-effective identification of hit compounds from any type of compound library, including our proprietary fragment library.
Concepts’ biology department has extensive experience in designing custom, streamlined and informative screening cascades providing consistently high quality, reliable data throughout the lifetime of a project.
Utilising our wealth of diverse assay experience we can build screening cascades to include biochemical, biophysical, phenotypic and cellular assays and select relevant orthogonal techniques to quickly identify false positives.
We offer flexibility to adjust and modify assays within a cascade during the lifetime of a project to ensure the most efficient and cost-effective path is taken to progress the hit matter.
The suite of instruments available to us ensures highly accurate dosing by digital dispensing with minimal compound usage, and the ability to evaluate a wide range of assay readouts including FP, HTRF and BRET. Data analysis is achieved through our bespoke software which is also used to produce clear and concise reports to our clients.
Concept’s biology team supports projects through the provision of consistent and robust iterative screening to ensure the most time-efficient and cost-efficient design-make-test-analyse cycle.
Due to co-location with our synthetic, medicinal, computational chemistry and ADMET colleagues this cycle time is further reduced, as no shipping of the compounds between laboratories is required.
Our automated liquid-handling capabilities enables fast turnaround of routine screening data, whether test compounds are analysed at a single concentration or over a full concentration range to generate dose-response curves and IC50 data. Our expertise in a large number of assay formats ensures we can combine multiple binding, activity and cellular assays to identify and optimise compounds for further development.
Concept has extensive capabilities in fragment-based drug discovery, offering access to expertise in screening, as well as computational and medicinal chemistry.
We offer a bespoke fragment library of around 1500 compounds with 100’s of unique structures. A comprehensive suite of biophysical instrumentation means we can offer orthogonal fragment screening for customised fragment-based lead discovery programs across a wide array of target types.
Our fragment-based lead discovery platform provides access to a number of biophysical technologies such as SPR, MST and ITC, as well as orthogonal biochemical or cellular activity assays.
Due to our co-location with both computational and medicinal chemistry support, we are able to expediate fragment hit expansion and optimisation, ensuring the hit to lead time is as short as possible.
Concept’s immunology expertise offers high throughput phenotypic screening of small molecules or biologics for their ability to drive phenotypic and functional immune cell changes, particularly in the tumour microenvironment.
Using the latest technology and automated platforms, custom assays can be miniaturised to 384-well plate approaches and high-content, multiplexed analysis performed producing fast, robust results.